Biologic drugs have emerged as a promising treatment to manage symptoms in some individuals with asthma. This form of medication is considered effective in controlling the condition and offering relief. Supported by extensive research and expert opinions, the use of biologic drugs in managing asthma symptoms is gaining traction. However, not all medical practitioners are familiar with this form of treatment, highlighting the need for continued education among healthcare providers.
Table of Contents
Physician Familiarity with Biologic Treatments
A survey presented at the 2023 American College of Allergy, Asthma and Immunology annual scientific meeting revealed that 42% of primary care physicians had limited experience with biological therapies for asthma. Many were unaware of the criteria for initiating such treatments, including the need for laboratory assessments. The delay in referrals to asthma specialists was often until patients had experienced multiple exacerbations within a year. The research indicated a need for enhanced communication between primary care physicians and asthma care specialists, particularly regarding biologic treatments. Experts also emphasized the importance of ongoing asthma education for physicians and the need for patients to actively participate in the management of their health.
Switching to Dupilumab
Studies have evaluated the switch from biological therapy to dupilumab in patients with severe asthma and comorbid chronic rhinosinusitis with nasal polyps. The outcomes, evaluated over 18 months, showed consistent improvement in all areas, along with consistent peripheral eosinophilia. Despite a few patients interrupting the therapy due to various causes, most patients benefited from the switch, with improved control in both the upper and lower airway.
Managing Severe Asthma with Tezspire
Tezspire, a biologic drug that belongs to a class called monoclonal antibodies, is prescribed for severe asthma in adults and some children. The typical dosage for adults is 210mg by injection once every four weeks, the same dosage applies for children aged 12 years and older. Tezspire, administered as a subcutaneous injection, is meant to be a long-term treatment. The importance of adhering to the prescribed dosage to avoid overdosing is emphasized. Tezspire shares some similarities with Xolair, another drug for severe asthma, but they differ in terms of each dose’s timing, strength, and approved uses.
Home Self-Injection of Biologics
A survey administered to Japanese patients using a pen-type device for home self-injection of biologics for severe allergic diseases showed that most participants wished to continue self-injection. The main reasons were the reduction in copayment and time saved from hospital visits. While a few patients denied continuation due to high cost, pain, or side effects, most were more than satisfied with the effectiveness of the biologics. The respondents, mostly low to middle income earners, affirmed that home self-injections and a 12-week prescription for biologics and other control medications significantly reduced their financial burden and hospital visits.
To wrap up, while biologic drugs show promising results in managing asthma symptoms, it is crucial for primary care physicians to understand these treatments better. Patient education is equally important to ensure effective asthma management. The potential benefits of biologic drugs are evident, but more research is needed to personalize therapy for patients with asthma and other comorbidities.
